IGC PHARMA, INC.— Sankey Diagram

Annual mode · period ending 2025-09-30 · SEC EDGAR

FY2025 - Q4(Jul 25 · Aug 25 · Sep 25)
Total Assets
$10M
↓-6.0% -$626Kvs FY2024
Total Liabilities
$2M
↓-44.8% -$1Mvs FY2024
Equity
$8M
↑+9.7% +$715Kvs FY2024
Cash
$1M
↓-28.5% -$441Kvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the annual mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2025FY2024
Total Assets$10M$10M
Current Assets$2M$4M
Cash$1M$2M
ST Investments$25K$0
Receivables$41K$44K
Inventory$658K$2M
Other Current$175K$1M
Non-Current Assets$8M$6M
PPE$2M$3M
Goodwill$0$0
Intangibles$5M$2M
Investments$0$0
Other Non-Current$685K$848K
Total Liab+Eq$10M$10M
Current Liab.$2M$3M
Accounts Payable$628K$768K
Short-Term Debt$4K$3K
Deferred Revenue$0$0
Other CL$882K$2M
Non-Current Liab.$137K$190K
Long-Term Debt$132K$135K
Other LT Liab.$5K$55K
Equity$8M$7M
Retained Earnings$123M$118M
Other Equity$0$0

QuarterCharts · SEC EDGAR data · IGC · Comparing FY2025 vs FY2024